Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21. doi: 10.1073/pnas.1111497108. Epub 2011 Aug 8.

2.

Different B cell populations mediate early and late memory during an endogenous immune response.

Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK.

Science. 2011 Mar 4;331(6021):1203-7. doi: 10.1126/science.1201730. Epub 2011 Feb 10.

3.

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC.

J Exp Med. 2011 Jan 17;208(1):181-93. doi: 10.1084/jem.20101352. Epub 2011 Jan 10. Erratum in: J Exp Med. 2011 Feb 14;208(2):411.

4.

Swine outbreak of pandemic influenza A virus on a Canadian research farm supports human-to-swine transmission.

Forgie SE, Keenliside J, Wilkinson C, Webby R, Lu P, Sorensen O, Fonseca K, Barman S, Rubrum A, Stigger E, Marrie TJ, Marshall F, Spady DW, Hu J, Loeb M, Russell ML, Babiuk LA.

Clin Infect Dis. 2011 Jan 1;52(1):10-8. doi: 10.1093/cid/ciq030.

5.

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.

Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84. doi: 10.1073/pnas.1013387107. Epub 2010 Oct 18.

6.

Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model.

Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG.

J Infect Dis. 2010 Oct 1;202(7):1011-20. doi: 10.1086/656188.

7.

Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P.

MBio. 2010 May 18;1(1). pii: e00018-10. doi: 10.1128/mBio.00018-10.

8.

Chiropteran types I and II interferon genes inferred from genome sequencing traces by a statistical gene-family assembler.

Kepler TB, Sample C, Hudak K, Roach J, Haines A, Walsh A, Ramsburg EA.

BMC Genomics. 2010 Jul 21;11:444. doi: 10.1186/1471-2164-11-444.

9.

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ.

Science. 2010 Aug 27;329(5995):1060-4. doi: 10.1126/science.1192517. Epub 2010 Jul 15.

10.

Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.

Kashyap AK, Steel J, Rubrum A, Estelles A, Briante R, Ilyushina NA, Xu L, Swale RE, Faynboym AM, Foreman PK, Horowitz M, Horowitz L, Webby R, Palese P, Lerner RA, Bhatt RR.

PLoS Pathog. 2010 Jul 8;6(7):e1000990. doi: 10.1371/journal.ppat.1000990.

11.

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A.

J Clin Invest. 2010 May;120(5):1663-73. doi: 10.1172/JCI41902. Epub 2010 Apr 12.

12.

Viral shedding and clinical illness in naturally acquired influenza virus infections.

Lau LL, Cowling BJ, Fang VJ, Chan KH, Lau EH, Lipsitch M, Cheng CK, Houck PM, Uyeki TM, Peiris JS, Leung GM.

J Infect Dis. 2010 May 15;201(10):1509-16. doi: 10.1086/652241.

13.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

14.

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P.

PLoS Pathog. 2010 Feb 26;6(2):e1000796. doi: 10.1371/journal.ppat.1000796.

15.

Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses.

Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, Hai R, Basler CF, Crowe JE Jr.

J Virol. 2010 Mar;84(6):3127-30. doi: 10.1128/JVI.02184-09. Epub 2009 Dec 30.

16.

Update on influenza A (H1N1) 2009 monovalent vaccines.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Oct 9;58(39):1100-1.

17.

Update: influenza activity--United States, April-August 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Sep 18;58(36):1009-12.

18.

Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans.

Zaas AK, Chen M, Varkey J, Veldman T, Hero AO 3rd, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R, Øien NC, Nicholson B, Kingsmore S, Carin L, Woods CW, Ginsburg GS.

Cell Host Microbe. 2009 Sep 17;6(3):207-17. doi: 10.1016/j.chom.2009.07.006. Epub 2009 Aug 6.

19.

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ; Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52. Erratum in: MMWR Recomm Rep. 2009 Aug 21;58(32):896-7.

20.

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.

Items per page

Supplemental Content

Write to the Help Desk